Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8230888 | International Journal of Radiation Oncology*Biology*Physics | 2011 | 8 Pages |
Abstract
This prospective trial using P-EBRT with HDR boost and hypofractionated dose escalation demonstrates a strong dose-response relationship for intermediate- and high-risk prostate cancer patients. The improvement at 10 years for locoregional control with higher radiation doses (BED, > 268Gy) has significantly decreased biochemical and clinical failures as well as distant metastasis.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Alvaro A. M.D., F.A.C.R., Jose M.D., Hong M.S., Mihai M.D., Ph.D., Sugandh M.D., Kenneth M.D., Gary M.D., Daniel M.D., Frank M.D., Larry M.D.,